Treatment of chancroid, 1989

Area of Science:

• Infectious Diseases
• Bacteriology
• Pharmacology

Background:

• Chancroid treatment guidelines were last updated in 1985.
• Erythromycin and ceftriaxone were the primary recommended treatments.
• Emerging data on alternative therapies and treatment efficacy is crucial.

Purpose of the Study:

• To evaluate the current efficacy of recommended and alternative therapies for chancroid.
• To assess the impact of human immunodeficiency virus (HIV) coinfection on treatment outcomes.
• To provide updated recommendations for chancroid management.

Main Methods:

• Review of in vitro and in vivo data on various antibiotic regimens.
• Analysis of clinical experience with different treatment protocols.
• Comparison of treatment success rates across different drug therapies.

Main Results:

• Erythromycin and ceftriaxone continue to demonstrate high efficacy against chancroid.
• Trimethoprim-sulfamethoxazole and amoxicillin-clavulanic acid appear effective, with limited US data.
• Single-dose trimethoprim-sulfamethoxazole is no longer considered an effective regimen.
• Ciprofloxacin shows favorable results, suggesting potential utility of quinolones.
• HIV coinfection is associated with higher treatment failure rates, possibly requiring extended therapy.

Conclusions:

• Erythromycin and ceftriaxone remain reliable first-line treatments for chancroid.
• Alternative regimens like trimethoprim-sulfamethoxazole and amoxicillin-clavulanic acid are viable options.
• HIV-positive patients with chancroid may require prolonged treatment courses for successful eradication.